Oxford, UK – 6 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that Tim Watts, Chief Financial Officer, will be presenting at the Jefferies 2016 Healthcare… Read More
Oxford, UK – 7 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive licence under Oxford BioMedica’s LentiVector… Read More
Unique combination of Oxford BioMedica’s LentiVector® delivery platform and Green Cross LabCell’s NK cell platform to generate a pipeline of differentiated products in cancer… Read More
Oxford, UK – 17 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, is pleased to announce that it has appointed Jefferies Hoare Govett as Sole Corporate Broker with… Read More
Oxford, UK – 12 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces today that Dr Paul Blake will leave the Group when his current contract expires at… Read More
Oxford, UK – 6 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today announces that new data has been presented from two clinical studies indicating ground-breaking long-term four-year… Read More
Encore is InterCall’s recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen again. The Recording will be available four… Read More
London, UK – 26 April 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today announces the appointment of Stuart Henderson as a non-executive Director of the Company and Chair… Read More
Oxford, UK – 7 March 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announced a new and expanded collaboration with Immune Design Corp. (“Immune Design”), a clinical-stage immunotherapy… Read More
Oxford, UK – 29 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces today that the Group has initiated work on a second Chimeric Antigen Receptor T cell… Read More
– New manufacturing facility fully operational – Creates extra capacity for wholly-owned pipeline, Novartis partnership and other new potential customers… Read More